{
    "clinical_study": {
        "@rank": "65662", 
        "brief_summary": {
            "textblock": "The purpose of this study is to see if ALRT1057 gel is safe and effective in treating\n      Kaposi's sarcoma (KS) when applied to skin ."
        }, 
        "brief_title": "A Study of ALRT 1057 Topical Gel in Patients With AIDS-Related Kaposi's Sarcoma", 
        "condition": [
            "Sarcoma, Kaposi", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Sarcoma, Kaposi", 
                "AIDS-Related Opportunistic Infections", 
                "Sarcoma"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a Phase 3 double-blind study. KS patients are randomized to 1 of 2 treatment arms.\n      They receive either ALRT1057 gel or placebo for 12 weeks. If progressive disease for KS is\n      noted before Week 12, patients are switched to the other blinded treatment arm. If a\n      response or disease progression that has not persisted for at least 4 weeks as of Week 12\n      occurs, treatment on the blinded arm is continued for up to 4 additional weeks, or until\n      response of disease progression is confirmed. After that time or after 12 weeks of\n      treatment, open-label ALRT1057 may be received."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Information not available"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002439", 
            "org_study_id": "272A", 
            "secondary_id": [
                "L1057T-31", 
                "96ACR-LIG1"
            ]
        }, 
        "intervention": {
            "intervention_name": "Alitretinoin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Alitretinoin"
        }, 
        "lastchanged_date": "June 23, 2005", 
        "official_title": "Randomized Phase III Vehicle Controlled Trial of ALRT 1057 Topical Gel in Patients With AIDS-Related Kaposi's Sarcoma", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "reference": {
            "PMID": "10770343", 
            "citation": "Walmsley S, Northfelt DW, Melosky B, Conant M, Friedman-Kien AE, Wagner B. Treatment of AIDS-related cutaneous Kaposi's sarcoma with topical alitretinoin (9-cis-retinoic acid) gel. Panretin Gel North American Study Group. J Acquir Immune Defic Syndr. 1999 Nov 1;22(3):235-46."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002439"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "collaborator": {
                "agency": "Ligand Pharmaceuticals", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Anderson Clinical Research", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 1997"
    }, 
    "geocoordinates": {}
}